Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
13 March 2014Website:
http://www.galmedpharma.comNext earnings report:
21 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:18:14 GMTDividend
Analysts recommendations
Institutional Ownership
GLMD Latest News
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
What type of business is Galmed Pharmaceuticals?
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
What sector is Galmed Pharmaceuticals in?
Galmed Pharmaceuticals is in the Healthcare sector
What industry is Galmed Pharmaceuticals in?
Galmed Pharmaceuticals is in the Biotechnology industry
What country is Galmed Pharmaceuticals from?
Galmed Pharmaceuticals is headquartered in Israel
When did Galmed Pharmaceuticals go public?
Galmed Pharmaceuticals initial public offering (IPO) was on 13 March 2014
What is Galmed Pharmaceuticals website?
https://www.galmedpharma.com
Is Galmed Pharmaceuticals in the S&P 500?
No, Galmed Pharmaceuticals is not included in the S&P 500 index
Is Galmed Pharmaceuticals in the NASDAQ 100?
No, Galmed Pharmaceuticals is not included in the NASDAQ 100 index
Is Galmed Pharmaceuticals in the Dow Jones?
No, Galmed Pharmaceuticals is not included in the Dow Jones index
When was Galmed Pharmaceuticals the previous earnings report?
No data
When does Galmed Pharmaceuticals earnings report?
The next expected earnings date for Galmed Pharmaceuticals is 21 November 2024